Ubs Group Ag Fennec Pharmaceuticals Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 11,223 shares of FENC stock, worth $44,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,223

Previous 7,268 54.42%

Holding current value

$44,779

Previous $44,000 27.27%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.85 - $6.73 $19,181 - $26,617	3,955 Added 54.42%	11,223 $56,000
Q2 2024 Aug 13, 2024	SELL	$6.02 - $10.99 $134,547 - $245,626	-22,350 Reduced 75.46%	7,268 $44,000
Q1 2024 May 13, 2024	BUY	$8.82 - $11.12 $85,104 - $107,296	9,649 Added 48.32%	29,618 $329,000
Q4 2023 Feb 09, 2024	BUY	$6.48 - $11.61 $64,663 - $115,856	9,979 Added 99.89%	19,969 $224,000
Q3 2023 Nov 09, 2023	SELL	$7.15 - $8.94 $3,875 - $4,845	-542 Reduced 5.15%	9,990 $75,000
Q2 2023 Aug 11, 2023	BUY	$7.27 - $9.82 $71,442 - $96,501	9,827 Added 1393.9%	10,532 $92,000
Q1 2023 May 12, 2023	BUY	$7.38 - $10.35 $4,730 - $6,634	641 Added 1001.56%	705 $5,000
Q4 2022 Feb 08, 2023	SELL	$7.63 - $10.22 $23,157 - $31,017	-3,035 Reduced 97.93%	64 $0
Q3 2022 Nov 10, 2022	BUY	$5.71 - $8.54 $17,329 - $25,918	3,035 Added 4742.19%	3,099 $26,000
Q2 2022 Aug 10, 2022	SELL	$5.17 - $6.33 $5,335 - $6,532	-1,032 Reduced 94.16%	64 $0
Q1 2022 May 16, 2022	SELL	$4.29 - $6.08 $28,661 - $40,620	-6,681 Reduced 85.91%	1,096 $6,000
Q4 2021 Feb 14, 2022	BUY	$3.89 - $10.01 $30,003 - $77,207	7,713 Added 12051.56%	7,777 $34,000
Q3 2021 Nov 15, 2021	SELL	$6.51 - $9.62 $383,582 - $566,829	-58,922 Reduced 99.89%	64 $1,000
Q2 2021 Aug 13, 2021	BUY	$5.96 - $7.85 $109,765 - $144,573	18,417 Added 45.4%	58,986 $430,000
Q1 2021 May 12, 2021	BUY	$6.21 - $8.68 $229,887 - $321,324	37,019 Added 1042.79%	40,569 $252,000
Q4 2020 Feb 11, 2021	BUY	$5.99 - $8.55 $21,264 - $30,352	3,550 New	3,550 $26,000
Q3 2020 Nov 12, 2020	SELL	$5.19 - $10.17 $35,743 - $70,040	-6,887 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$5.43 - $9.39 $37,396 - $64,668	6,887 New	6,887 $58,000
Q1 2020 May 01, 2020	SELL	$4.89 - $8.1 $4,806 - $7,962	-983 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$4.25 - $6.49 $5,605 - $8,560	-1,319 Reduced 57.3%	983 $6,000
Q3 2019 Nov 14, 2019	BUY	$3.85 - $4.95 $8,450 - $10,865	2,195 Added 2051.4%	2,302 $11,000
Q2 2019 Aug 14, 2019	SELL	$3.3 - $5.09 $673 - $1,038	-204 Reduced 65.59%	107 $0
Q1 2019 May 14, 2019	SELL	$4.64 - $7.58 $31,941 - $52,180	-6,884 Reduced 95.68%	311 $2,000
Q4 2018 Feb 14, 2019	BUY	$5.37 - $8.39 $23,606 - $36,882	4,396 Added 157.06%	7,195 $46,000
Q3 2018 Nov 14, 2018	SELL	$7.84 - $10.83 $11,712 - $16,180	-1,494 Reduced 34.8%	2,799 $23,000
Q2 2018 Aug 14, 2018	BUY	$10.05 - $14.33 $43,144 - $61,518	4,293 New	4,293 $45,000
Q1 2018 May 15, 2018	SELL	$8.26 - $12.1 $6,715 - $9,837	-813 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$8.9 - $12.35 $6,532 - $9,064	734 Added 929.11%	813 $8,000
Q3 2017 Nov 14, 2017	BUY	$11.09 - $12.0 $876 - $948	79	79 $1,000

Others Institutions Holding FENC

# of Institutions

Shares Held

14.9M

Call Options Held

10K

Put Options Held

83.8K

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $104M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account